Showing 4731-4740 of 6803 results for "".
- Possible Eczema Breakthrough? S. aureus May Promote Skin Inflammation via IL-36-Mediated T Cell Responseshttps://practicaldermatology.com/news/possible-eczema-breakthrough-s-aureus-may-promotes-skin-inflammation-via-il-36-mediated-t-cell-responses/2457978/Toxin-producing bacteria on the surface of our skin may induce a protein that causes our own cells to react and cause inflammation, according to research published online in Cell Host & Microbe. <
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/asds-elects-new-officers-board-members/2457995/Members of the
- Chris Greta Appointed Chief Creative Officer at eRelevancehttps://practicaldermatology.com/news/chris-greta-appointed-chief-creative-officer-at-erelevance/2457996/Chris Greta has been appointed as the first chief creative officer for
- Menlo Therapeutics Expands Management Teamhttps://practicaldermatology.com/news/menlo-therapeutics-expands-management-team/2458006/Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the treatment of pruritus associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to ad
- PruGen Pharmaceuticals Takes Action to Aid Hurricane Relief Effortshttps://practicaldermatology.com/news/prugen-pharmaceuticals-takes-action-to-aid-hurricane-relief-efforts/2458007/In the wake of several devastating and destructive hurricanes in the continental US and Puerto Rico, PruGen Pharmaceuticals is helping to those in need. The PruGen Foundation, a nonprofit organization founded by PruGen Pharmaceuticals and focused on philanthropic
- Ortho Dermatologics: Long-term Efficacy Data for Siliqhttps://practicaldermatology.com/news/ortho-dermatologics-long-term-efficacy-data-for-siliq/2458009/Siliq™ (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis, according to data presented at the 2017 Fall Clinical Dermatology Conference in Las Vegas and reported by
- ASDS Elects New Officers, Board Membershttps://practicaldermatology.com/news/asds-elects-new-officers-board-members/2458016/The American Society for Dermatologic Surgery (ASDS) introduced their new Vice Presid
- EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe ADhttps://practicaldermatology.com/news/eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad/2458050/Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (C
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for
- Women of Color May Be Disproportionately Exposed to Beauty Product Chemicalshttps://practicaldermatology.com/news/women-of-color-may-be-disproportionately-exposed-to-beauty-product-chemicals/2458087/Women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women, according to a commentary published in the American Journal of Obstetrics and Gynecology.<